Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Heterogeneous response of airway eosinophilia to anti-IL-5 biologics in severe asthma patients
Authors:ID Kopač, Maruša, Klinika Golnik (Author)
ID Rijavec, Matija, Klinika Golnik, Biotehniška fakulteta UL (Author)
ID Korošec, Peter, Klinika Golnik, Fakulteta za farmacijo (Author)
ID Bidovec, Urška, Klinika Golnik (Author)
ID Kern, Izidor, Klinika Golnik (Author)
ID Vantur, Romana, Klinika Golnik (Author)
ID Škrgat, Sabina, Klinika Golnik, Medicinska fakulteta UL, Univerzitetni klinični center Ljubljana (Author)
Files:.pdf PDF - Presentation file, download (805,99 KB)
MD5: 2D1E19734BDB21EEC30F6F74C9643323
URL URL - Source URL, visit
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Many questions concerning responders (R) and nonresponders (NR) in severe eosinophilic asthma (SEA) after blocking the IL-5 (interleukin 5) pathway are still not clear, especially regarding the early parameters of response to biologics in personalized treatment strategies. We evaluated 17 SEA patients treated with anti-IL-5 biologics (16 patients mepolizumab, one patient benralizumab) before the introduction of biologics, and at a week 16 follow-up. Clinical, cellular and immunological parameters in peripheral blood were measured in R and NR. Sputum induction with the measurement of cellular and immunological parameters was performed at 16 weeks only. There were 12 R and 5 NR to biologics. After 16 weeks, there was a significant improvement in percentages of FEV1 (p = 0.001), and asthma control test (ACT) (p = 0.001) in the R group, but not in NR. After 16 weeks, the eosinophils in induced sputum were 27.0% in NR and 4.5% in R (p = 0.05), with no difference in IL-5 concentrations (p = 0.743). Peripheral eosinophilia decreased significantly in NR (p = 0.032) and R (p = 0.002). In patients with SEA on anti-IL-5 therapy, there was a marked difference in airway eosinophilic inflammation between R and NR already at 16 weeks, after anti-IL-5 introduction.
Year of publishing:2022
Publication status in journal:Published
Article version:Publisher's version of article
Number of pages:str. 1-12
Numbering:Vol. 12, iss. 1
ISSN on article:2075-4426
DOI:10.3390/jpm12010070 New window
COBISS.SI-ID:92821507 New window
Copyright:© 2022 by the authors
Note:Nasl. z nasl. zaslona; Maruša Kopač Šokić in Matija Rijavec sta enakovredna prva avtorja; Opis z dne 11. 1. 2022; Članek št. 70;
Publication date in DiRROS:13.01.2022
AddThis uses cookies that require your consent. Edit consent...

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Journal of personalized medicine
Shortened title:J. pers. med.
COBISS.SI-ID:31207641 New window


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:07.01.2022

Secondary language

Keywords:težka astma, anti-IL-5 biološka zdravila, eozinofilija, dihalne poti, sputum